Enveda · funding
Enveda Raises $311 Million Series E at $2 Billion Valuation
Enveda has closed a $311 million Series E that gives the private biotech more capital to advance three clinical-stage drug programs and expand its AI drug-discovery platform.
Has Enveda actually closed the $311 million financing?
Yes. Enveda announced the Series E closed on September 23, 2026, led by Catalio Capital Management.
Orbitrum Investor Impact
Why does the funding matter for Enveda?
The financing extends Enveda's ability to fund later-stage clinical development rather than stopping at drug discovery. Clinical success is still uncertain, and the capital does not mean its medicines will reach approval.
What valuation did Enveda receive?
TechCrunch reported a $2 billion valuation, about double the valuation from its financing 12 months earlier. The $2 billion figure is the company's valuation, not the amount of new capital raised.
What will Enveda use the money for?
Enveda plans to advance ENV-294 and ENV-308 into later-stage trials, move ENV-6946 through mid-stage testing, bring additional inflammatory and metabolic programs into clinical trials, and expand its PRISM platform and automated laboratory.
How much capital has Enveda raised in total?
The Series E brings Enveda's total capital raised since inception to more than $845 million.
What should investors watch next?
Enveda expects new trials for ENV-294 and ENV-308 to begin in the coming months, while additional ENV-294 clinical data are scheduled to be presented on October 1, 2026.
Sources
- Enveda — Enveda Raises $311 Million From Leading AI and Biotech Investors to Bring Pharma Into the 21st Century
- TechCrunch — Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Original signal: TechCrunch ↗
See more Orbitrum in Google
Add Orbitrum as a Preferred Source to make our research more likely to appear for you in Google Search.